IMDX Insight Molecular Diagnostics Inc Forecast, Technical & Fundamental Analysis
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes... Show more
IMDX is expected to report earnings to rise 100.00% to -23 cents per share on August 06
Q2'26
Est.
$-0.24
Q1'26
Beat
by $0.53
Q4'25
Missed
by $0.16
Q3'25
Beat
by $0.24
Q2'25
Beat
by $0.33
The last earnings report on May 13 showed earnings per share of -11 cents, beating the estimate of -64 cents. With 32.63K shares outstanding, the current market capitalization sits at 150.15M.
A.I. Advisor
published General Information
General Information
a developer of ovel, non-invasive, liquid biopsy diagnostics for the early detection of cancer
A.I.dvisor indicates that over the last year, IMDX has been loosely correlated with STRRP. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if IMDX jumps, then STRRP could also see price increases.
Momentum Indicator for IMDX turns negative, indicating new downward trend
IMDX saw its Momentum Indicator move below the 0 level on July 29, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned negative. In of the 88 cases, the stock moved further down in the following days. The odds of a decline are at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for IMDX turned negative on July 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .
IMDX moved below its 50-day moving average on July 07, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IMDX crossed bearishly below the 50-day moving average on July 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The 50-day moving average for IMDX moved below the 200-day moving average on July 29, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMDX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for IMDX entered a downward trend on July 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IMDX advanced for three days, in of 208 cases, the price rose further within the following month. The odds of a continued upward trend are .
IMDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. IMDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (196.078) is normal, around the industry mean (69.994). P/E Ratio (0.000) is within average values for comparable stocks, (159.234). IMDX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.659). IMDX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.007). IMDX's P/S Ratio (78.125) is very high in comparison to the industry average of (8.241).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
